Genmab has agreed to acquire Merus for approximately $8 billion, a strategic move aimed at enhancing its late-stage cancer treatment pipeline with a promising bispecific antibody candidate that recently exhibited positive Phase II results. The acquisition will incorporate Merus’ lead asset, petosemtamab, which has garnered attention for its potential in treating head and neck cancer.
This acquisition aligns with Genmab’s goal of transitioning from partnered to wholly owned assets, thereby diversifying its revenue streams and positioning the company for sustained growth in the coming decade. The integration of Merus’ innovative pipeline is expected to bolster Genmab’s standing as a leader in biotechnology, particularly in the realm of antibody therapies.
Petosemtamab, an EGFRxLGR5 bispecific antibody, has received two Breakthrough Therapy Designations from the FDA, underscoring its potential to become a first-in-class treatment. With a promising overall survival rate of 79% reported in a Phase II trial, Genmab anticipates that petosemtamab could generate significant annual sales, further solidifying its market position. This acquisition, if completed, would mark one of the largest biotech mergers of 2025, highlighting the competitive landscape in oncology therapeutics.
Start your 7-day trial and see what the database can do →
